MiNK Therapeutics CEO Jennifer Buell sells 6,938 shares

Q: How many shares did INKT CEO Jennifer Buell sell, and at what price?

Jennifer Buell sold 6,938 common shares on October 12, 2026, at a weighted average of $10.56 per share. The trades ranged from $10.33 to $10.61 and were solely to satisfy tax withholding obligations incurred upon vesting; no Rule 10b5-1 plan is reported.

Q: How many INKT shares did Jennifer Buell receive from RSUs?

On October 11, 2026, Jennifer Buell converted 23,191 RSUs into 23,191 common shares. Each RSU represents a contingent right to receive one common share, and 46,382 RSUs were reported after the conversion.

The 2023 award was adjusted from 695,750 to 69,573 RSUs to reflect MiNK's 1-for-10 reverse stock split on January 28, 2025.

Filing Impact

(Neutral)

Filing Sentiment

(Negative)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

Rhea-AI Filing Summary

MiNK Therapeutics, Inc. CEO and director Jennifer Buell converted 23,191 restricted stock units into 23,191 common shares on October 11, 2026, then sold 6,938 common shares on October 12 at a weighted average of $10.56 per share. The sale was solely to satisfy tax withholding obligations incurred upon vesting; trade prices ranged from $10.33 to $10.61. The reported remaining position was 46,382 RSUs, and no Rule 10b5-1 plan is reported.

Insider Trade Summary

Exercise and sale activity reported; no spread calculated

Exercise and Sale 3 txns

Insider Buell Jennifer

Role Chief Executive Officer

Sold 6,938 shs ($73K)

Approx. gross sale proceeds $73K

Type	Security	Shares	Price	Value
Sale	Common Stock ^{F2, F3}	6,938	$10.56	$73K
Exercise	Restricted Stock Units ^{F1, F4}	23,191	$0.00	$0.00
Exercise	Common Stock ^F1	23,191	--	--

Holdings After Transaction: Restricted Stock Units — 46,382 contracts (Direct); Common Stock — 74,195 shares (Direct)

Footnotes (4)

F1. Each restricted stock unit ("RSU") represents a contingent right to receive one share of common stock of MiNK Therapeutics, Inc. (the "Company").
F2. Represents sales of shares, as a consequence of the vesting of restricted stock units, solely to satisfy tax withholding obligations incurred upon vesting.
F3. Represents a weighted average price. The shares were sold in multiple transactions at prices ranging from $10.33 to $10.61. The reporting person undertakes to provide to the Company, any shareholder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F4. On October 11, 2023 the reporting person was granted RSUs under the Company's 2021 Equity Incentive Plan, vesting in three substantially equal annual installments on each of the third, fourth and fifth anniversaries of the grant date. This award was previously reported as covering 695,750 RSUs but was adjusted to 69,573 RSUs to reflect the 1-for-10 reverse stock split (rounding) that occurred on January 28, 2025.

Key Figures

Common shares sold: 6,938 shares Weighted average sale price: $10.56 per share Sale price range: $10.33–$10.61 per share +3 more

6 metrics

Common shares sold 6,938 shares October 12, 2026; sale to satisfy tax withholding upon vesting

Weighted average sale price $10.56 per share October 12, 2026

Sale price range $10.33–$10.61 per share Multiple transactions on October 12, 2026

Restricted stock units converted 23,191 RSUs October 11, 2026

Common shares acquired upon conversion 23,191 shares October 11, 2026

RSUs following conversion 46,382 RSUs Reported after the October 11, 2026 conversion

Key Terms

restricted stock unit, weighted average price, tax withholding obligations, reverse stock split

4 terms

restricted stock unit financial

"Each restricted stock unit ("RSU") represents a contingent right to receive one share"

A restricted stock unit is a promise from a company to give an employee shares of stock after certain conditions are met, like staying with the company for a set amount of time. It’s like earning a bonus that turns into company stock once you’ve proven your commitment, making it a way to motivate and reward employees.

weighted average price financial

"Represents a weighted average price."

Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.

tax withholding obligations financial

"solely to satisfy tax withholding obligations incurred upon vesting."

reverse stock split financial

"1-for-10 reverse stock split (rounding)"

A reverse stock split reduces a company's number of outstanding shares while raising the price per share proportionally, so the total value of each investor's holding is unchanged; a 1-for-10 split turns 100 shares worth $1 each into 10 shares worth $10 each. Companies often do this to regain compliance with an exchange's minimum price rule or to attract investors who avoid very low-priced stocks.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many shares did INKT CEO Jennifer Buell sell, and at what price?

Jennifer Buell sold 6,938 common shares on October 12, 2026, at a weighted average of $10.56 per share. The trades ranged from $10.33 to $10.61 and were solely to satisfy tax withholding obligations incurred upon vesting; no Rule 10b5-1 plan is reported.

How many INKT shares did Jennifer Buell receive from RSUs?

On October 11, 2026, Jennifer Buell converted 23,191 RSUs into 23,191 common shares. Each RSU represents a contingent right to receive one common share, and 46,382 RSUs were reported after the conversion.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Available on EDGAR 10/14/2026 - 02:37 PM EDT Accepted by SEC EDGAR 10/14/2026 - 02:36 PM EDT

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Buell Jennifer

(Last)

(First)

(Middle)

149 FIFTH AVENUE, SUITE 500

(Street)

NEW YORK

10010

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
MiNK Therapeutics, Inc. [ INKT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	Chief Executive Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
10/11/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	10/11/2026		M		23,191	A	⁽¹⁾	81,133	D
Common Stock	10/12/2026		S		6,938⁽²⁾	D	$10.56⁽³⁾	74,195	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Restricted Stock Units	⁽¹⁾	10/11/2026		M			23,191	⁽⁴⁾	⁽⁴⁾	Common Stock	23,191	$0.00	46,382	D

Explanation of Responses:

1. Each restricted stock unit ("RSU") represents a contingent right to receive one share of common stock of MiNK Therapeutics, Inc. (the "Company").

2. Represents sales of shares, as a consequence of the vesting of restricted stock units, solely to satisfy tax withholding obligations incurred upon vesting.

3. Represents a weighted average price. The shares were sold in multiple transactions at prices ranging from $10.33 to $10.61. The reporting person undertakes to provide to the Company, any shareholder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

4. On October 11, 2023 the reporting person was granted RSUs under the Company's 2021 Equity Incentive Plan, vesting in three substantially equal annual installments on each of the third, fourth and fifth anniversaries of the grant date. This award was previously reported as covering 695,750 RSUs but was adjusted to 69,573 RSUs to reflect the 1-for-10 reverse stock split (rounding) that occurred on January 28, 2025.

	/s/ Melissa Orilall, as Attorney-in-Fact for Jennifer Buell	10/14/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR